ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Integrated BioPharma Inc (QX)

Integrated BioPharma Inc (QX) (INBP)

0.19
0.00
( 0.00% )
Actualizado: 07:16:44

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
0.19
Postura de Compra
0.172
Postura de Venta
0.20
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.17 Rango de 52 semanas 0.327
Capitalización de Mercado [m]
Precio Anterior
0.19
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
2,918
Acciones en circulación
30,099,610
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-172.73
Beneficio por acción (BPA)
-0
turnover
50.67M
Beneficio neto
-34k

Acerca de Integrated BioPharma Inc (QX)

Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the "Company"), is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company does business as Chem International, Inc. with certain of... Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the "Company"), is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company does business as Chem International, Inc. with certain of its customers and certain vendors. The Company's business segments include: (a) Contract Manufacturing operated by InB:Manhattan Drug Company, Inc. ("MDC"), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. ("AgroLabs"), which distributes healthful nutritional products for sale through major mass market, grocery, drug and vitamin retailers, and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory which sells private label MDC products, as well as our AgroLabs products, through the Internet, (ii) IHT Health Products, Inc. ("IHT") a distributor of fine natural botanicals, including multi minerals produced under a license agreement, (iii) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfilment services and (iv) Chem International, Inc., a distributor of certain raw materials for DSM Nutritional Products LLC. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
1970
Integrated BioPharma Inc (QX) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker INBP. The last closing price for Integrated BioPharma (QX) was US$0.19. Over the last year, Integrated BioPharma (QX) shares have traded in a share price range of US$ 0.17 to US$ 0.327.

Integrated BioPharma (QX) currently has 30,099,610 shares in issue. The market capitalisation of Integrated BioPharma (QX) is US$5.72 million. Integrated BioPharma (QX) has a price to earnings ratio (PE ratio) of -172.73.

INBP Últimas noticias

INOVIO Reports Inducement Grant Under Inducement Plan

INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., Aug. 1, 2024 PLYMOUTH MEETING, Pa., Aug. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology...

Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 PR Newswire PLYMOUTH MEETING, Pa., July...

INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024

INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLYMOUTH MEETING, Pa., July 25, 2024 PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO...

INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway

INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway PR Newswire PLYMOUTH MEETING, Pa., July 11, 2024 Award recognizes the...

INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer PR Newswire PLYMOUTH MEETING, Pa., July 2, 2024 Mr. Egge brings over 25 years of biopharmaceutical experience building...

INOVIO Reports Inducement Grant Under Inducement Plan

INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., July 1, 2024 PLYMOUTH MEETING, Pa., July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology...

INOVIO Added to Russell 2000® Index Effective July 1, 2024

INOVIO Added to Russell 2000® Index Effective July 1, 2024 PR Newswire PLYMOUTH MEETING, Pa., July 1, 2024 PLYMOUTH MEETING, Pa., July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a...

INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.

INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc. PR Newswire PLYMOUTH MEETING, Pa., June 4, 2024 PLYMOUTH MEETING, Pa., June 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a...

INOVIO Reports Inducement Grants Under Inducement Plan

INOVIO Reports Inducement Grants Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., May 31, 2024 PLYMOUTH MEETING, Pa., May 31, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.013657.740289197620.176350.190.173168710.19CS
40.0158.571428571430.1750.20.17369130.19186548CS
12-0.039-17.03056768560.2290.250.17329180.20572337CS
26-0.025-11.62790697670.2150.250.17356930.21254857CS
52-0.11009-36.68566096840.300090.3270.1794400.2371049CS
156-0.75-79.78723404260.941.180.17105330.68766321CS
260-0.038-16.66666666670.2281.250.17121720.70104862CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WTERAlkaline Water Company Inc (CE)
US$ 0.001
(99,900.00%)
201
EBIXQEbix Inc (CE)
US$ 0.001
(99,900.00%)
75.03k
MCETMultiCell Technologies Inc (CE)
US$ 0.0002
(19,900.00%)
100
MLFBMajor League Football Inc (CE)
US$ 0.000123
(12,200.00%)
163
INTKIndustrial Nanotech Inc (PK)
US$ 0.0001
(9,900.00%)
2.06M
STABStatera BioPharma Inc (CE)
US$ 0.000001
(-99.83%)
300
OWVIOne World Ventures Inc (CE)
US$ 0.000045
(-99.55%)
447
TTCFQTattooed Chef Inc (CE)
US$ 0.000001
(-99.50%)
2.08k
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.000001
(-99.00%)
2.45M
BRAVBravada International Limited (CE)
US$ 0.000001
(-99.00%)
180
ASIIAccredited Solutions Inc (PK)
US$ 0.0011
(-15.38%)
246.87M
EMEDElectroMedical Technologies Inc (PK)
US$ 0.0007
(40.00%)
169.23M
PPJEPPJ Healthcare Enterprises Inc (PK)
US$ 0.0001
(-50.00%)
117.5M
PRSTPresto Automation Inc
 0.0036
(-81.91%)
73.06M
AAPJAAP Inc (PK)
US$ 0.0001
(0.00%)
59.35M

INBP Discussion

Ver más
greasemonkeyshoes greasemonkeyshoes 4 años hace
Added few more shares.....
this baby is on fire and chieeeeppppppppppppppp!
👍️0
bobkubecka bobkubecka 4 años hace
INBP 10k filed
https://www.otcmarkets.com/filing/html?id=13912523&guid=lQACUKuJUTjIW3h
👍️0
Golden Cross Golden Cross 5 años hace
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2019
Press Release | 11/13/2019
HILLSIDE, NJ / ACCESSWIRE / November 13, 2019 / Integrated BioPharma, Inc. (OTC BB:INBP) (the "Company") reports it financial results for the quarter ended September 30, 2019.

Revenue for the quarter ended September 30, 2019 was $11.4 million compared to $10.3 million for the quarter ended September 30, 2018, an increase of $1.1 million or 10.7%. The Company had operating income for the quarter ended September 30, 2019 of $0.5 million compared to operating income of $0.4 million for the quarter ended September 30, 2018.

For the quarter ended September 30, 2019, the Company had net income and diluted net income of $0.3 million or $0.01 per share of common stock, compared with net income and diluted net income of $0.2 million or $0.01 per share of common stock for the quarter ended September 30, 2018.

"We are excited to report that our revenue increased by approximately 11% in the quarter ended September 30, 2019 and that our revenue from our two significant customers in our Contract Manufacturing Segment remained consistent; representing approximately 91% and 89% of total revenue in the quarters ended September 30, 2019 and 2018, respectively," said Riva Sheppard, Co-Chief Executive Officer of the Company.

A summary of our financial results for the three months ended September 30, 2019 follows:

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(unaudited)
Three Months Ended
September 30,
2019 2018
Total revenue
$ 11,406 $ 10,304
Cost of sales
10,007 9,085
Gross profit
1,399 1,219
Selling and administrative expenses
923 814
Operating income
476 405
Other expense, net (1)
(127 ) (191 )
Income before income taxes
349 214
Income tax expense, net
37 55
Net income
$ 312 $ 159
Net income per common share:
Basic
$ 0.01 $ 0.01
Diluted
$ 0.01 $ 0.01
Weighted average common shares outstanding:
Basic
29,565,943 27,218,786
Diluted
30,724,633 27,963,604
(1) Includes interest expense of $124 and $200, respectively.
SOURCE: Integrated BioPharma, Inc.



View source version on accesswire.com:
https://www.accesswire.com/566451/Integrated-BioPharma-Reports-Results-for-its-Quarter-Ended-September-30-2019
👍️0
bobkubecka bobkubecka 5 años hace
INBP 10k filed
https://www.otcmarkets.com/filing/html?id=13618471&guid=-U6IUe4whcTGP3h
👍️0
bonedaddy77 bonedaddy77 5 años hace
I'm surprised there isn't more love here. I saw Q3 financials and they look pretty good.
👍️0
greasemonkeyshoes greasemonkeyshoes 5 años hace
eps=3c.....
or 12c x 5(pe) = 60c stock in the making.wooowwwww.
👍️0
greasemonkeyshoes greasemonkeyshoes 5 años hace
Not bad....
Revenue up 11%
eps .008c or 3.2c annualized
inventory is up $2.0 million,must expect $12+ million shipment next few quarters.
👍️0
greasemonkeyshoes greasemonkeyshoes 5 años hace
Yes,for q2 which ended on 12/31/18......
ER due out most likely today.This company has many moving parts,I hope $500k operating income stays up,generating enough cash and lower their debt level due in 2020.Once inbp got its act together,top line of $10+ million/q can do a lot of damage(in a positive way).
👍️0
Knowledge is King Knowledge is King 5 años hace
Is this a prediction for the 12/18 Q?
👍️0
greasemonkeyshoes greasemonkeyshoes 5 años hace
This ER numbers........
rev 11.4 million
cost 10.0 million(88%)
sg&a 0.85 million(7%)
net income 0.28 million(2%) or 1c
forward pe@13c:
13c/1c*4=3.3
👍️0
greasemonkeyshoes greasemonkeyshoes 6 años hace
Buy.....
q4(6/30/18):
revenue up 12%
net income $818k w/change of derivative&others $461k(benefit).
or
this dog is getting rid of its flee,1 or 2 more q to go,before complete eradication.Wooowwwww.
👍️0
greasemonkeyshoes greasemonkeyshoes 6 años hace
10Q pending.......
This dog with flee is on the move.A good q coming??
👍️0
greasemonkeyshoes greasemonkeyshoes 6 años hace
$5.3 million of convertible debt to equity @65c........
With current quote of the stock at 16c,the greatest thing since the sliced of bread just occured,a gift to the shareholders/company.Nothing can be better than this event.Wooowwwwww.
Bottom line to the capital structure:
$4.0 million net debt reduction,at no dilution to its shareholders.
Saving of $318k of interest expense annually.
👍️0
aetosellinas aetosellinas 10 años hace
What a week INBP & IBIO
I smell some HUGE gains here folks
👍️0
DChow DChow 10 años hace
Shhhhhhhhhhhhhhhhhhh
👍️0
aetosellinas aetosellinas 10 años hace
Oh they will :), very interesting week coming. Given how low the float is here, we may see some crazy runs here
👍️0
balamidas balamidas 10 años hace
...



👍️0
©PROPHETABLE ©PROPHETABLE 10 años hace
***MARK IT***


NEXT EBOLA RUNNER...

IF YOU'RE NOT LOADING, WE ARE...TIC...TOC...TIC...TOC...TIC...TOC...
👍️0
TradeSmart.ai TradeSmart.ai 10 años hace
Surprised more people haven't caught on to this yet ;]

$INBP
👍️0
aetosellinas aetosellinas 10 años hace
INBP-our hidden under the radar gem holding about 1.7 million shares of IBIO woweeee lol. This is going to get very interesting, with less the a million float who knows how high this can reach here. It's IBIO investment alone is about 5.5 million, what's to stop IBIO from surging up much more ahead if it's recent developments.
Things are going to get very interesting, too bad we're so under the radar, I'm sure that'll change :)
👍️0
aetosellinas aetosellinas 10 años hace
Monster is an understatement, market cap is so low and discounted and the float here is only like 1 million
It's crazy to see still at these levels, people haven't the slightest idea
👍️0
angelo2112 angelo2112 10 años hace
People starting to put 2&2 together I see... Nice!
This will be a monster runner mark it!
👍️0
tommie0908 tommie0908 10 años hace
Got me a starter position today
👍️0
GOLDMAN STACKS GOLDMAN STACKS 10 años hace
Boom!!!!
👍️0
©PROPHETABLE ©PROPHETABLE 10 años hace
Me likey!!!
👍️0
Talc Moan Talc Moan 10 años hace
I thought you knew for some reason lol!
👍️0
MONEYMADE MONEYMADE 10 años hace
NOW YA TELL ME!!! HAHAA NICE FIND
👍️0
Talc Moan Talc Moan 10 años hace
INBP valuation is going through the roof. 21 mill OS and 70% owned by insiders. They own 1.2 million shares of IBIO now valued at almost 3 million dollars.

The share price will keep rising with Ibio's advancement.
👍️0
Sibware Sibware 10 años hace
Well.Houston.We have an INdescriBable Problem==>

I AM your wife.

Been following you since a while, without you knowing it...

Ebola Fever??? Huh!!!!

I'm gonna show you what a fever feels like, tonight!!!



Can you hear me???

👍️0
CDBLEG CDBLEG 10 años hace
Whats your opinion on this chart here? Been following it and trying to see where this is going. Newbie here
👍️0
Talc Moan Talc Moan 10 años hace
LOL... Tell my wife that plzzzzzz
👍️0
Sibware Sibware 10 años hace
LMAO! At least, he's good at something...
👍️0
Talc Moan Talc Moan 10 años hace
Nah just a pumper "LOL"
👍️0
Sibware Sibware 10 años hace
You know him too??? They say he's very good...
👍️0
Talc Moan Talc Moan 10 años hace
Lmao!
👍️0
Sibware Sibware 10 años hace
Heard_they_have_an advisor named smitter or something like that...Lol...
👍️0
Talc Moan Talc Moan 10 años hace
Make you go hmmmmmmmmmmm
👍️0
Talc Moan Talc Moan 10 años hace
Yep, and they prob have some insider knowledge of what is going on over at IBIO.
👍️0
Sibware Sibware 10 años hace
I'm sure they know when's the best time to sell some of their IBIO shares...

What will be interesting also is, what will they do with all that money>>>>

👍️0
Talc Moan Talc Moan 10 años hace
They own 1.2 mill IBIO. They better hold it. IBIO gonna be $10+ prob less than a few weeks. This company is going to be cash heavy!
👍️0
Sibware Sibware 10 años hace
INBP: Cash coming in... ***
👍️0
Talc Moan Talc Moan 10 años hace
The higher IBIO goes the more Value this gets and exposure.
👍️0
aetosellinas aetosellinas 10 años hace
.30 next .38-.42
👍️0
Talc Moan Talc Moan 10 años hace
.28+++
👍️0
aetosellinas aetosellinas 10 años hace
Here we go, watch volume this moves like crazy could see .50 today plus
👍️0
aetosellinas aetosellinas 10 años hace
Pop to 30's-45+++
Be ready
👍️0
Talc Moan Talc Moan 10 años hace
.22
👍️0
Talc Moan Talc Moan 10 años hace
Investment in iBio, Inc. The Company accounts for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it retained approximately 6% of its interest in iBio (1,266,706 common shares) (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008. The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be an impairment of the investment. There were impairment charges of $152 and $139 recorded in the fiscal years ended June 30, 2014 and 2013, respectively. The market value of the iBio Stock as of June 30, 2014, was approximately $0.5 million. Pursuant to the Company’s Loan Agreement with PNC Bank, National Association (“PNC”), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. In the fiscal years ended June 30, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days. (See Note 6. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt). As of September 8, 2014, the Company has not sold any shares of the iBio Stock.




Looks like they are gonna be CASH HEAVY soon LOL!
👍️0
willlbone willlbone 10 años hace
Very small float.
👍️0
DUKES BOY DUKES BOY 10 años hace
Scramracing I'm in Pphm left this thing in 2012
👍️0